Crispr Therapeutics shares tumble after significant earnings miss

Published 04/08/2025, 22:20
Crispr Therapeutics shares tumble after significant earnings miss

Investing.com -- CRISPR Therapeutics (NASDAQ:CRSP) reported a wider-than-expected loss for the second quarter of 2025, sending shares down 6.1% as both earnings and revenue fell significantly short of analyst expectations.

The gene-editing company posted a second quarter loss of $2.40 per share, substantially worse than the analyst estimate of $1.40 per share. Revenue came in at just $890,000, far below the consensus estimate of $5.81 million. The disappointing results were primarily driven by higher-than-expected acquired in-process R&D expenses of $96.3 million related to the company’s recent agreement with Sirius Therapeutics.

Despite the financial miss, CRISPR Therapeutics highlighted progress in its commercial rollout of CASGEVY, its gene therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company has activated 75 authorized treatment centers globally, with approximately 115 patients completing their first cell collection and 29 patients receiving infusions through June 30.

"We are entering the second half of the year with momentum across both our commercial and clinical programs," said Samarth Kulkarni, Ph.D., Chairman and CEO of CRISPR Therapeutics. "The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance."

The company’s cash position stood at $1.72 billion as of June 30, 2025, down from $1.90 billion at the end of 2024. R&D expenses decreased to $69.9 million from $80.2 million YoY, while general and administrative expenses slightly decreased to $18.9 million from $19.5 million in the same period last year.

CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas, including its in vivo liver editing programs CTX310 and CTX320, as well as next-generation allogeneic CAR T product candidates CTX112 and CTX131. The company expects to present complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.